Clinical Trials, Phase III as Topic
Research News and Information

Sunday, November 22, 2009

Microbicides development programme: engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania.

7 Oct 2009 BACKGROUND: HIV prevention research in resource-limited countries is associated with a variety of ethical dilemmas. Key amongst these is the question of what constitutes an appropriate standard of health care (SoC) for participants in HIV prevention ... Read more...

GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.

29 Sep 2009 BACKGROUND: Gonadotropin-releasing hormone (GnRH) analogues are used routinely to prevent a premature luteinizing hormone (LH) surge in women undergoing assisted reproductive technology (ART) treatments. In contrast to GnRH agonists, antagonists ... Read more...

[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy]

29 Sep 2009 PURPOSE: The purpose of the present article was to evaluate indications, regimens, treatment modalities, and predictive factors of response to treatment in locally advanced squamous cell carcinoma of the head and neck (SCCHN). METHODS: An expert ... Read more...

Latest indexed articles for 'Clinical Trials, Phase III as Topic'

These are the very latest articles for this heading:

• Novel pharmacotherapies for obesity poised to enter market. 30 Oct 2009
• First oral therapies for multiple sclerosis anticipated. 30 Oct 2009
• Microbicides development programme: engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania. 7 Oct 2009
• GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. 29 Sep 2009
• [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy] 29 Sep 2009
• Mixed results for novel CD20-targeted antibody. 29 Sep 2009
• Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary: in regard to Lefebvre et al., for the larynx preservation consensus panel (Int J Radiat Oncol Biol Phys 2009;73:1293-1303). 29 Sep 2009
• Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. 29 Sep 2009
• A developing country response to Lavery et al. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?". 28 Sep 2009
• HIV vaccine reduces infection rate by a third, study shows. 23 Sep 2009
• Maintenance therapy in non-small-cell lung cancer. 16 Sep 2009
• PARP inhibitors: will the new class of drugs match the hype? 6 Sep 2009
• Lymphoma vaccine trial: one step forward in long trek. 6 Sep 2009
• Malignant pleural mesothelioma: current treatments and emerging drugs. 30 Aug 2009
• Adalimumab safety in global clinical trials of patients with Crohn's disease. 30 Aug 2009
• Performance-based readability testing of participant information for a Phase 3 IVF trial. 30 Aug 2009
• Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. 30 Aug 2009
• Hematology: Azacitidine improves survival in myelodysplastic syndromes. 30 Aug 2009
• Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. 30 Aug 2009
• B cell depletion in lupus and Sjögren's syndrome: an update. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Clinical Trials, Phase III as Topic'

Definition: Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.

Descriptor UI: D017326

Alternative terms: Clinical Trials, Phase III as Topic; Clinical Trials, Phase 3 as Topic; Evaluation Studies, FDA Phase III as Topic; Drug Evaluation, FDA Phase III as Topic; Drug Evaluation, FDA Phase 3 as Topic; Evaluation Studies, FDA Phase 3 as Topic;

Allowable Qualifiers: adverse effects; classification; economics; history; instrumentation; methods; mortality; nursing; psychology; standards; trends; utilization; veterinary; statistics & numerical data; contraindications; ethics; legislation & jurisprudence;

Tree Number: E05.318.760.535.220; E05.337.250.220; N05.715.360.775.235.220; N06.850.520.450.535.220;

History Note: 2008(1993)

Technical Notes: for general design, methodology, economics, etc. of phase III clinical trials; a different heading CLINICAL TRIAL, PHASE III is used for reports of a specific phase III clinical trial